Odyssey Therapeutics, Inc.
NASDAQ:ODTXBiotechnology
-$0.01 today
- Market cap
- $912.33M
- Beta
- 0.00
Volume 0.37M
Average 0.43M
ODTX Other Non-Cash Items
Other non-cash adjustments that reconcile net income to operating cash flow.
Other Non-Cash Items history
Currency unavailable · from the cash flow
No Other Non-Cash Items data reported for this period type.
Other Non-Cash Items vs competitors
How ODTX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $133.92M USD | +1446.6% | +117.4% | 47.5% | |
| LTM Mar 2026 | $78.61M USD | +42.2% | -12.8% | 33.8% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $44.46M USD | +123.1% | +1204.6% | 601.0% |
| LTM Sep 2026 | $33.58M USD | -41.1% | — | 37.1% | |
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | $14.93M USD | +1516.1% | +227.4% | — |
| LTM Mar 2026 | $4.76M USD | -94.7% | -21.2% | 56.9% | |
| LTM Mar 2026 | $595K USD | +331.5% | -76.4% | — | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | — | — | — | — | — |
| Peer median (excluding ODTX) | — | +123.1% | +52.3% | 47.5% | |
Competitors are the stored peer set for ODTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Odyssey Therapeutics, Inc.
NASDAQ:ODTX
Intrinsic Alpha fair value
Locked
Current Price
$18.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.